NOI Sole Source - IntestiCult Organoid Growth Medium (Human) - StemCell Technologies
Closed Pre-Solicitation Posted
- Solicitation number
- 87872-2024
- Agency
-
CDC Office of Acquisition Services
Centers for Disease Control and Prevention, Department of Health and Human Services
- Responses due
- Set-aside
- No set-aside
Opportunity facts
- NAICS code
- 541714 Research and Development in Biotechnology (except Nanobiotechnology)
- Place of performance
- Atlanta, Georgia 30341, United States
- Points of contact
Notice details come from SAM.gov. Updated .
About this opportunity
First Paragraph:
The Centers for Disease Control and Prevention (CDC), National Center for Immunization and Respiratory Diseases (NCIRD), Division of Viral Diseases (DVD), intends to award a sole source, firm fixed-price purchase order to StemCell Technologies for the acquisition of IntestiCult Organoid Growth Medium (Human) cell culture media. This media is essential for CDC's research on human norovirus, as it contains the necessary growth factors to culture adult intestinal stem cells derived from human intestinal crypts. The use of this specialized media is integral to CDC's projects related to modeling the intestinal epithelium, studying intestinal diseases, and screening for efficacy and toxicity. The statutory authority for this sole source acquisition is 10 U.S.C 2304(c)(1), and the acquisition will be conducted as a simplified procurement under FAR Part 13.
Second Paragraph:
This procurement does not have any set-aside designation. StemCell Technologies is the sole source provider of the required IntestiCult Organoid Growth Medium (Human), as they are the only manufacturer of this specialized cell culture media. The NAICS code for this requirement is 541714 for Biotechnology Research and Development, and the PSC code is AN11 for Health R&D Services. Interested parties are invited to submit capability statements demonstrating their ability to meet this requirement by August 22, 2024, but the government will make a determination on whether to compete the contract based solely on its own discretion.
Notice text
The Centers for Disease Control and Prevention (CDC), National Center for Immunization and Respiratory Diseases (NCIRD), Division of Viral Diseases (DVD), hereby announces its intent to issue an award a sole source, firm fixed-price purchase order to StemCell Technologies for the purchase of cell culture media, IntestiCult™ Organoid Growth Medium (Human).
StemCell Technologies is the only source that can provide the cell culture media, IntestiCult™ Organoid Growth Medium (Human) because it contains growth factors for the intestinal cells to grow. CDC has established the culture of adult intestinal stem cells derived from human intestinal crypts in support of several projects related to human norovirus. Applications of intestinal organoid cultures include studying the development and function of intestinal epithelium, modeling intestinal diseases, screening molecules for both efficacy and toxicity as well as the immune response to infection, and environmental studies. Model key characteristics of the adult intestinal epithelium using intestinal organoids were established and maintained with IntestiCult™ Organoid Growth Medium (Human) formulation.
The statutory authority for this sole source acquisition is 10 U.S.C 2304(c)(1) in accordance with FAR Part 13.106-1(b) Simplified Acquisition Procedures only one responsible source and no other supplies or services will satisfy the agency requirement. The sole source procurement will be awarded as a simplified acquisition in accordance with FAR Part 12 and FAR Subpart 13 procedures. The NAICS code for this request is 541714, (Biotechnology research and development laboratories or services in the medical sciences (except nanobiotechnology research and development).
THIS NOTICE OF INTENT IS NOT A REQUEST FOR COMPETITIVE QUOTATIONS; however, all responses received within 15 days of the issuance of this notice will be reviewed by the Government. A determination by the Government not to compete this proposed contract based upon responses to this notice is solely within the discretion of the Government. Interested parties who believe they possess the capabilities to satisfy this requirement should submit a capability statement demonstrating their abilities to meet this requirement. Any response must be emailed to the contract specialist Felipe Cardenas at tpp5@cdc.gov by August 22, 2024. No phone calls will be accepted.
Similar open opportunities
On GovTribe
Work this opportunity
- Track it in your pipeline
- Find teaming partners
- Similar opportunities
- Ask GovTribe AI about this opportunity